Drug-induced chronic urticarias;Urticaires chroniques d'origine médicamenteuse

Annales de Dermatologie et de Venereologie

Volumn 130, Issue SPEC. ISS. 1, 2003, Pages

  Mathelier Fusade, P ^a  

^a HÔPITAL TENON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBODY; COMPLEMENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOGLOBULIN E; NONSTEROID ANTIINFLAMMATORY AGENT; BIOGENIC AMINE; FOOD ADDITIVE; FOOD ALLERGEN; FOOD DYE; HISTAMINE; NICKEL; PENICILLIN G;

ANGIONEUROTIC EDEMA; ANTIGEN ANTIBODY COMPLEX; CHRONIC URTICARIA; COMPLEMENT ACTIVATION; CONFERENCE PAPER; DRUG ERUPTION; DRUG HYPERSENSITIVITY; HUMAN; MAST CELL; MEDIATOR RELEASE; PROTEIN DEGRADATION; PROTEIN INDUCTION; RASH; ACUTE DISEASE; ALLERGIC REACTION; ANISAKIS; AUTOIMMUNE DISEASE; CONTACT URTICARIA; DIET; DISEASE ASSOCIATION; FISH; FOOD ALLERGY; FOOD CONTAMINATION; FOOD INTAKE; HISTAMINE METABOLISM; IDIOPATHIC DISEASE; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOLOGY; LARVA; MEAT; MEDICAL LITERATURE; MEDLINE; MILK; PHYSICAL URTICARIA; PRICK TEST; PROVOCATION TEST; PSEUDOALLERGY; SENSITIZATION; SYMPTOM; URTICARIA;

ANGIONEUROTIC EDEMA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRADYKININ; CHRONIC DISEASE; COMPLEMENT ACTIVATION; DRUG ERUPTIONS; HUMANS; TIME FACTORS; URTICARIA; ADMINISTRATION, ORAL; ADULT; BIOGENIC AMINES; CHILD; DIAGNOSIS, DIFFERENTIAL; DOUBLE-BLIND METHOD; FOOD ADDITIVES; FOOD CONTAMINATION; FOOD HYPERSENSITIVITY; HISTAMINE RELEASE; IMMUNOGLOBULIN E;

EID: 0038345549     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (28)

1. Beltrani VS. An overview of chronic urticaria. Clin Rev Allergy Immunol 2002;143:147-69.
2. Shipley D, Ormerod AD. Drug-induced urticaria: recognition and management. Am J Clin Dermatol 2001;2:151-8.
3. Kaplan AP. Chronic urticaria and angioedema. N Engl J Med 2002;346:175-9.
4. Juhlin L. Recurrent urticaria: clinical investigation of 330 patients. Br J Dermatol 1981;104:369-81.
5. Kozel MMA, Mekkes JR, Bossuyt PM, Bos JD. The effectivenes of a history-based diagnostic approach in chronic urticaria and angioedema. Arch Dermatol 1998;134:1575-80.
6. Doeglas HM. Reactions to aspirin and food additives in patients with chronic urticaria including physical urticarias. Br J Dermatol 1975;93:135-44.
7. Genton C, Frei P, Pecoud A. Value of oral provocation tests to aspirin and food additives in the routine investigation of asthma and chronic urticaria. J Allergy Clin Immunol 1985;76:40-5.
8. James J, Warin RP. Chronic urticaria: the effect of aspirin. Br J Dermatol 1970;82:204-5.
9. Wright AL, Minford A. Urticaria and hidden salicylates. Pediatr Dermatol 1999;16:463-4.
10. Katz Y, Goldberg N, Kivity S. localized periorbital edema induced by aspirin. Allergy 1993;48:366-9.
11. Stevenson DD. Diagnosis, prevention, and treatment of adverse reactions to aspirin and nonsteroidal anti-inflammatory drugs. J Allergy Clin Immunol 1984;74:617-22.
12. Vane JR, Warner TD. Nomenclature for COX-2 inhibitors. Lancet 2000;356:1373-4.
13. Asero R. Leukotriene receptor antagonists may prevent NSAID-induced exacerbations in patients with chronic urticaria. Ann Allergy Asthma Immunol 2000;85:156-7.
14. Sanchez Borges M, Capriles-Hulett A, Caballero-Fonseca F, Perez CR. Tolerability to new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactions. Ann Allergy Asthma Immunol 2001;87:201-4.
15. Erbagci Z. The leukotriene receptor antagonist montelukast in the treatment of chronic idiopathic urticaria: a single-blind, placebo-controlled, crossover clinical study. J Allergy Clin Immunol 2002;110: 484-8.
16. Hedner T, Samuelsson O, Lunde H, Lindholm L, Andren L, Wiholm BE. Angio-edema in relation to treatment with angiotensin converting enzyme inhibitors. BMJ 1992;304:941-6.
17. Inman WH, Rawson NS, Wilton LV. Postmarketing surveillance of enalapril: results of prescription-event monitoring. BMJ 1988;297:826-9.
18. Slater EE, Merrill DD, Guess HA. Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition. JAMA 1988; 260:967-70.
19. Kozel MMA, Mekkes JR, Bos JD. Increased frequency and severity of angioedema related to long-term therapy with angiotensin-converting enzyme inhibitor in two patients. Clin Exp Dermatol 1995;20:60-1.
20. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 1992;117:234-42.
21. Berkun Y, Shalit M. Hereditary angioedema first apparent in the ninth decade during treatment with ACE inhibitor. Ann Allergy Asthma Immunol 2001;87:138-9.
22. Kleiner GI, Giclas P, Stadtmauer G, Cunningham-Rundles C. Unmasking of acquired autoimmune C1-inhibitor deficiency by an angiotensin-converting enzyme inhibitor. Ann Allergy Asthma Immunol 2001;86: 461-4.
23. Nussberg J, Cugno M, Cicardi M. Bradykinin-mediated angioedema. N Engl J Med 2002;347:621-2.
24. Molinaro G, Cugno M, Perez M, Lepage Y, Gervais N, Agostoni A et al. Angiotensin-converting enzyme inhibitor-associated angioedema is characterized by a slower degradation of des-arginine(9)-bradykinin. J Pharmacol Exp Ther 2002;303:232-7.
25. Van Rijnsoever EW, Kwee-Zwiderwijk WJ, Feenstra JA. Angioneurotic edema attributed to the use of losartan. Arch Int Med 1998;558:2063-5.
26. Warner KK, Visconti JA, Tschampel MM. Angiotensin II receptor blockers in patients with ACE inhibitor-induced angioedema. Ann Pharmacother 2000;34:526-8.
27. Lo KS. Angioedema associated with candesartan. Pharmacotherapy 2002;22:1176-9.
28. Bindsley-Jensen C, Finzi A, Greaves M, Camarasa J, Ortonne JP, Schopf E et al. Chronic urticaria: diagnostic recommendations. J Eur Acad Dermatol Venereol 2000;14:175-80.